IMRX News & Events

The S&P and Nasdaq added to their recent gains to kick off June as investors weigh continued U.S.-Iran tensions against continued strength in the AI trade. Oil prices jumped again as Iranian state media reported that the country's negotiators are ceasing communication with the U.S. and that Iran will completely close off the Strait of Hormuz because of Israel's attacks on Lebanon. However, President Trump said in response in a post to social media that talks arewith Iran. Nvidia led technology stocks higher following the launch of a new chip for PCs as traders continue to funnel money into AI-related names, semiconductors, data-center infrastructure, and power-generation plays.Get caught up quickly on the top news and calls moving stocks with these five Top Five lists.1. STOCK NEWS:Nvidiaunveiled adeveloped in partnership with Microsoftthat will be incorporated into a new RTX Spark chip for PCsTaylor Morrisonby Berkshire Hathawayfor $72.50 per share in cashWeatherfordNCS Multistagein a cash and stock transactionMcDonald'sannounced, the company's new strategy to unlock its "next phase of growth and productivity"Anthropic confidentially submitted a draft registration statement on Form S-1 to the SEC2. WALL STREET CALLS:Dell Technologiesto Equal Weight at Morgan StanleyCampbell'sto Equal Weight at StephensKohl'sto Buy at CitiRedwireto Hold at Jefferies following 223% advanceHawkEye 360with mostly Buy and equivalent ratings3. AROUND THE WEB:Applehas pushed into finance with a bill splitting service, Bloomberg reportsInteland 3DGS Inc. USA will invest about $3.3B to build a semiconductor substrate manufacturing plant in the Odisha's Bhubaneswar-Khurda region, Reuters reportsApproximately 1,000 workers at the American Axle plant in Three Rivers, Michigan are set to strike, which will stall production of key parts for certain General Motorstrucks, WSJ saysAppleis delaying iPhone-connected smart glasses to late 2027, aiming to disrupt the mid-tier $200-$500 eyewear market the way it disrupted the watch market, Bloomberg reportsSoftBankhas become Japan's largest company in market value, driven by AI demand and rising global investor interest in the sector, FT says4. MOVERS:Optimum Communicationswas higher after launching aMGM Resortsrose after People Incorporatedthe company for $48.30 per share in cashAMCgained after recording itsof May since 2019Immuneeringfell afterfrom its Phase 2a trial evaluating atebimetinib in combination with modified gemcitabine/nab-paclitaxelBlackSkywas lower after Jefferiesthe stock to Hold from Buy5. EARNINGS/GUIDANCE:Rapid7backed itsand FY26SAICand raised its guidance for FY27Humanareaffirmed itsCango, with EPS and revenue lower year-over-yearBroadcomwillon June 3, 2026INDEXES:The Dow rose 46.42, or 0.091%, to 51,078.88, the Nasdaq gained 114.19, or 0.42%, to 27,086.81, and the S&P 500 advanced 19.90, or 0.26%, to 7,599.96.

The major averages were mixed near noon as investors weigh escalating U.S.-Iran tensions against continued strength in the AI trade. Oil prices surged following weekend developments involving Iran, raising concerns that energy costs could once again become a source of inflation pressure. Of note, Iranian state media reported that the country's negotiators are ceasing communication with the U.S. and that Iran will completely close off the Strait of Hormuz because of Israel's attacks on Lebanon.Meanwhile, Nvidia led technology stocks higher following the launch of a new chip for PCs. The news comes as traders continue to funnel money into AI-related names, semiconductors, data-center infrastructure, and power-generation plays.Get caught up quickly on the top news and calls moving stocks with these five Top Five lists.1. STOCK NEWS:Nvidiadeveloped in partnership with Microsoftthat will be incorporated into a new RTX Spark chip for PCsTaylor Morrisonby Berkshire Hathawayfor $72.50 per share in cashPeople IncorporatedMGM Resortsfor $48.30 per share in cashWeatherfordNCS Multistagein a cash and stock transactionYum! Brandsis in exclusive talks to sell its Pizza Hut business to LongRange Capital,2. WALL STREET CALLS:Dell Technologiesto Equal Weight at Morgan StanleyCampbell'sto Equal Weight at StephensKohl'sto Buy at CitiRedwireto Hold at Jefferies following 223% advanceHawkEye 360with mostly Buy and equivalent ratings3. AROUND THE WEB:Inteland 3DGS Inc. USA will invest about $3.3B to build a semiconductor substrate manufacturing plant in the Odisha's Bhubaneswar-Khurda region, Reuters reportsApproximately 1,000 workers at the American Axle plant in Three Rivers, Michigan are set to strike, which will stall production of key parts for certain General Motorstrucks, WSJ saysMetahas agreed to pay about $27M to settle a lawsuit filed by a Kentucky school district, Bloomberg saysAppleis delaying iPhone-connected smart glasses to late 2027, aiming to disrupt the mid-tier $200-$500 eyewear market the way it disrupted the watch market, Bloomberg reportsSoftBankhas become Japan's largest company in market value, driven by AI demand and rising global investor interest in the sector, FT says4. MOVERS:Optimum Communicationshigher afterfor shares of stockREalloysincreases after announcing it will be included in theAMCgains after recording itssince 2019Immuneeringfalls afterfrom its Phase 2a trial evaluating atebimetinib in combination with modified gemcitabine/nab-paclitaxelBlackSkylower after Jefferiesthe stock to Hold from Buy5. EARNINGS/GUIDANCE:Rapid7for Q2 and FY26SAICand raised its guidance for FY27Humanafor FY26Cango, with EPS and revenue lower year-over-yearBroadcomon June 3, 2026INDEXES:Near midday, the Dow was down 0.22%, or 111.40, to 50,921.06, the Nasdaq was up 0.23%, or 61.30, to 27,033.92, and the S&P 500 was up 0.05%, or 4.09, to 7,584.15.

Immuneering announced updated clinical data from its ongoing Phase 2a trial evaluating atebimetinib in combination with modified gemcitabine/nab-paclitaxel in first-line metastatic pancreatic ductal adenocarcinoma. The data are being presented in an oral session at the 2026 American Society of Clinical Oncology, or ASCO. The presentation showcases data from an expanded cohort totaling 55 first-line pancreatic cancer patients. This open-label, single-arm Phase 2a trial evaluated atebimetinib at 320 mg once daily in combination with mGnP in participants with first-line metastatic pancreatic cancer, irrespective of mutational status. The company reported the following as of the April 24 data cutoff date. In the expanded 55-patient cohort, median overall survival was 17.3 months, compared to 8.5 months median overall survival in the pivotal Phase 3 MPACT study of standard of care gemcitabine/nab-paclitaxel. The median follow-up was 11.6 months. Median progression-free survival was 8.3 months, disease control rate was 82%, and the confirmed overall response rate was 36%. In the original 34-patient cohort with longer follow-up, median overall survival was also observed to be 17.3 months - supporting the consistency of the survival signal across cohorts with different durations of follow-up. Only two categories of Grade 3 or higher treatment-related adverse events occurred in at least 10% of participants, both related to chemotherapy. No Grade 4 adverse events related to atebimetinib and no Grade 5 treatment-related adverse events were reported. Only one participant discontinued atebimetinib while continuing mGnP. The safety profile observed in the trial compared favorably to historical experiences with intensive chemotherapy treatments and combination regimens under development in pancreatic cancer. Additionally, 84% of participants with available data maintained or gained weight at three months, a potentially important indicator of preserved performance status and tolerability in this patient population where cachexia is common and correlated with poorer outcomes.

"We are excited that new survival data from 55 first-line pancreatic cancer patients treated with atebimetinib + mGnP in our Phase 2a clinical trial will be reported in an oral presentation at the ASCO Annual Meeting on June 1st," said Ben Zeskind, CEO of Immuneering. "We believe the upcoming presentation at ASCO is an excellent opportunity to build on the recent momentum in second-line pancreatic cancer and demonstrate atebimetinib's potential to provide a differentiated first-line option for patients. Our Phase 3 study of atebimetinib + mGnP in first-line pancreatic cancer patients, MAPKeeper 301, is now recruiting patients, and we remain on track to dose the first patient by mid-2026. Our Phase 2 lung cancer trial is on track to dose the first patient in the second half of the year. I believe we are entering a new era in cancer care where treatments have the potential to drive longer survival with fewer harsh side effects, and that atebimetinib will play an important role in that future."